Thrombocythemia is also referred as essential thrombocythemia or primary thrombocythemia. Thrombocythemia is a rare chronic blood clotting disorder caused by bone marrow. It is a condition in which blood has higher platelets compare to normal platelets. The normal range of platelet in human blood is 150,000 to 450,000 per microliter. Blood clots can occur suddenly in patients suffering from thrombocythemia. Abnormal blood clotting can be fatal as it may block the flow of blood to the heart, brain, liver, or other organs. According to research, thrombocythemia is common in women and people over 50 years of age. Headache, chest pain, lightheadedness or dizziness, slightly enlarged spleen, fainting, changes in vision, weakness, numbness or tingling in feet or hands, redness, or throbbing are the common symptoms of thrombocythemia. Discharge of blood in urine, getting bruised easily, bleeding from nose or gums or mouth, or discharge of blood in stool are the rare symptoms of primary thrombocythemia. Shortness of breath, seizures, weakness or numbness in arm, leg, or face, or heart attack are high risk complications for thrombocythemia.

A complete blood count (CBC), blood smear, genetic testing (JAK2, CALR, or MPL gene), bone marrow aspiration, uric acid level are studied by healthcare professionals in order to diagnose thrombocythemia. Medical treatment of thrombocythemia depends on the severity of the disorder. Currently, hydroxyurea, anagrelide, interferon alfa, and low-dose aspirin are used commonly used for the treatment of thrombocythemia. In case of emergency, plateletpheres is also used to treat thrombocythemia. General prevalence of thrombocythemia is approximately 30 in 100,000 persons.  Rise in prevalence of thrombocythemia in the geriatric population drive the market globally.

The global thrombocythemia drugs market can be segmented based on medical treatment and region. In terms of medical treatment, the thrombocythemia drug market can be categorized into anti-platelet treatment, platelet-lowering treatment, alternative cytoreductive therapy, and others. Aspirin is the gold standard treatment of thrombocythemia. It reduces the symptoms of declined platelets count. Hydroxyurea is platelet-lowering treatment for thrombocythemia subjects. Interferon-α (IFN-α) also offers significant results in reducing the platelet number. Pipobroman is an alternative cytoreductive therapy which is proposed to control the platelet number in elderly patients with essential thrombocythemia. In terms of revenue, the anti-platelet treatment and platelet-lowering treatment segments hold major shares of the thrombocythemia drugs market globally.

Geographically, the global thrombocythemia drug market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. These regions can be further divided by countries and medical treatment. North America is the leading market for thrombocythemia drugs. In terms of revenue, the U.S. holds a major share of the thrombocythemia drugs market in North America. The thrombocythemia drug market in Europe is expanding rapidly due to increase in the number of elderly patients in the region. The thrombocythemia drug market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing countries such as China and India are anticipated to contribute to the growth of the thrombocythemia drug market in Asia Pacific between 2017 and 2025 due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increase in awareness among people in these countries. Brazil and Mexico dominate the thrombocythemia drug market in Latin America. South Africa, Turkey, and other developing countries in Middle East & Africa propel the thrombocythemia drug market in the region.

Key players operating in the global thrombocythemia drugs market are AstraZeneca plc, Intas Pharmaceuticals Ltd., Shire plc, Torrent Pharms Ltd., Teva Pharmaceutical Industries Ltd., Impax Laboratories, Inc., Otsuka Pharmaceutical Co., Ltd., Sandoz (Novartis AG), Luitpold Pharms Inc., Zydus Healthcare Ltd., and Cipla, Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Thrombocythemia Drug Market